Somatostatin News and Research

RSS

Novel preclinical model mimics persistent interneuron loss seen in preterm infants

Research-clinicians at Children's National Health System have created a novel preclinical model that mimics the persistent interneuron loss seen in preterm human infants, identifying interneuron subtypes that could become future therapeutic targets to prevent or lessen neurodevelopmental risks, the team reports Jan. 31, 2019, in eNeuro.

20 Feb 2019

Human cells can change their original function to battle against diabetes

For the first time, researchers have shown that ordinary human cells can change their original function. This may give new hope for diabetes patients.

14 Feb 2019

MGH researchers identify brain cells that modulate behavioral response to threats

A team of investigators from the Massachusetts General Hospital (MGH) Center for Regenerative Medicine has identified a population of brain cells that appears to play a role in calibrating behavioral responses to potentially threatening situations.

12 Feb 2019

Discovery may lead to new form of treatment for diabetes

Diabetes is caused by damaged or non-existing insulin cells inability to produce insulin, a hormone that is necessary in regulating blood sugar levels. Many diabetes patients take insulin supplements to regulate these levels.

7 Jan 2019

Researchers identify new region in mouse brain that affects appetite and body weight

Researchers at A*STAR's Singapore Bioimaging Consortium have identified a new region of the mouse brain called the Tuberal Nucleus, which affects appetite and body weight

13 Jul 2018

Study shows benefits, safety of long-lasting radionuclide therapy for patients with advanced NETs

A first-in-human study presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging demonstrates the benefits and safety of a new, long-lasting type of radionuclide therapy for patients with advanced, metastatic neuroendocrine tumors.

26 Jun 2018

New FDA-approved therapy provides better quality of life for patients with midgut neuroendocrine tumors

Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated Food and Drug Administration approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy.

12 Jun 2018

New nuclear medicine method appears to effectively detect neuroendocrine tumors

Researchers have shown that a new nuclear medicine procedure could safely and more effectively detect cancerous gastrointestinal and pancreatic neuroendocrine tumors than current methods.

7 Jun 2018

Scientists identify neural circuit that gives rise to anxiety

Neuroscientists at Cold Spring Harbor Laboratory have identified a neural circuit in the amygdala, the brain's seat of emotion processing, that gives rise to anxiety.

29 May 2018

FDA approves new radioactive drug for treatment of rare digestive tract cancers

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

29 Jan 2018

Researchers find surprising differences in first-ever whole-brain map of inhibitory neurons

Researchers at Penn State College of Medicine have collaborated on the first-ever quantitative whole-brain map of inhibitory neurons in the mouse brain. These brain cells play a crucial role in regulating response to stimuli and have been widely implicated in many psychiatric conditions.

6 Oct 2017

Novel peptide receptor radionuclide therapy improves wellbeing of neuroendocrine cancer patients

Malignant neuroendocrine tumors, commonly called NETs, are easy to miss and associated with discouraging survival rates and poor quality of life.

13 Jun 2017

Specialized nerve cells play key role in controlling information flow in the brain, study finds

Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert.

3 Mar 2017

Long-term clinical data, experience supports effectiveness of PRRT for treating neuroendocrine tumors

More than ten years of published clinical data and personal experience using PRRT-based targeted therapy of neuroendocrine tumors supports the effectiveness of this novel treatment approach and the ability to minimize and manage potential toxic side effects.

17 Oct 2016

Molecular imaging technique could help optimize radiotherapy dose to combat NETs

Aggressive neuroendocrine cancer is something of a dark horse--a rare, elusive and persevering force linked to discouraging long-term survival rates.

14 Jun 2016

Genetic blood test can help predict patient’s respone to neuroendocrine cancer therapy

Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. According to research presented at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, an investigative blood test could predict how patients will respond to peptide receptor radionuclide therapy (PRRT) before they commit to a course of treatment.

14 Jun 2016

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

Advanced imaging kit Netspot gets FDA approval to detect rare neuroendocrine tumors

The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging.

2 Jun 2016

Altered circadian somatostatin expression linked to bipolar disorder

Results of the first study of its kind to link abnormalities in circadian rhythms to changes in specific neurotransmitters in people with bipolar disorder will be published this week in the journal Biological Psychiatry.

1 Jun 2016

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.

26 Feb 2016